Chemistry:FV-100
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
| |
| Systematic IUPAC name
3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one | |
| Other names
Cf1743
| |
| Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
| UNII | |
| |
| Properties | |
| C22H26N2O5 | |
| Molar mass | 398.459 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
FV-100, also known as Cf1743, is an orally available nucleoside analogue drug[1] with antiviral activity.[2] It may be effective against shingles.[3]
It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium.[4]
Clinical trials
FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb.[5] The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey.[6] It has reached Phase III clinical trials.[7]
References
- ↑ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009, http://www.medicalnewstoday.com/articles/138537.php
- ↑ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy 64 (4): 671–673. doi:10.1093/jac/dkp294. PMID 19679595.
- ↑ Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264. doi:10.1002/jmv.24750 PMID 27943311
- ↑ Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100., http://www.cardiff.ac.uk/phrmy/contactsandpeople/fulltimeacademicstaff/mcguiganchrisshinglesdrugfv100.html Shows structure of FV100.
- ↑ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015, http://clinicaltrials.gov/ct2/show/NCT00900783
- ↑ ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial., January 2015, http://www.dddmag.com/news/2015/01/contravir-pharmaceuticals-fda-meeting-about-antiviral-drug-trial?et_cid=4352306&et_rid=297252576&type=cta
- ↑ De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi:10.1128/CMR.00102-15 PMID 27281742
 |  |
